[
  {
    "ts": null,
    "headline": "A First Take On CG Oncology",
    "summary": "CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.",
    "url": "https://finnhub.io/api/news?id=1a6cc91e0715e5e770fc0e23f70a2b35b26914926f44eecb335d62f79b4b39ba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736528174,
      "headline": "A First Take On CG Oncology",
      "id": 132371715,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.",
      "url": "https://finnhub.io/api/news?id=1a6cc91e0715e5e770fc0e23f70a2b35b26914926f44eecb335d62f79b4b39ba"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ae115ca671eda4e2848d4b706ec63c4b86e20ade9106a76196c392c26aaabbd1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736526720,
      "headline": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
      "id": 132408340,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ae115ca671eda4e2848d4b706ec63c4b86e20ade9106a76196c392c26aaabbd1"
    }
  },
  {
    "ts": null,
    "headline": "High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower",
    "summary": "Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for risk-tolerant investors. See more here.",
    "url": "https://finnhub.io/api/news?id=cbec3b655141026a8080e3cb9f043dc126b78def306bad017e0bb5407a84c48a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736480293,
      "headline": "High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower",
      "id": 132358957,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1269090428/image_1269090428.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for risk-tolerant investors. See more here.",
      "url": "https://finnhub.io/api/news?id=cbec3b655141026a8080e3cb9f043dc126b78def306bad017e0bb5407a84c48a"
    }
  }
]